Blog Viewer

SITC Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events Published in JITC

By SITC Scientific Publications News posted 06-25-2021 00:00

  
The “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events” was published in JITC June 25, 2021. While ICIs have improved patient outcomes in a number of clinical settings, the same mechanisms that underpin their effective anti-tumor properties may cause unique toxicities, specifically immune-related adverse events (irAEs). As ICIs increasingly become integrated into treatment plans for an ever-increasing number of disease settings, there is a need for clear, expert guidance on the recognition and management of irAEs. SITC convened an expert panel to develop this clinical practice guideline with evidence- and consensus-based recommendations to assist medical professionals in clinical decision-making and improve outcomes for patients.

June 25, 2021

Permalink